CN107998305A - 一种用于治疗冠心病的中药配方 - Google Patents
一种用于治疗冠心病的中药配方 Download PDFInfo
- Publication number
- CN107998305A CN107998305A CN201810081654.XA CN201810081654A CN107998305A CN 107998305 A CN107998305 A CN 107998305A CN 201810081654 A CN201810081654 A CN 201810081654A CN 107998305 A CN107998305 A CN 107998305A
- Authority
- CN
- China
- Prior art keywords
- heart disease
- coronary heart
- chinese medicine
- radix
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title claims abstract description 70
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 50
- 239000000463 material Substances 0.000 claims abstract description 37
- OEYQBKYISMRWQB-UHFFFAOYSA-N Santal Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C(O)=C1 OEYQBKYISMRWQB-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000009636 Huang Qi Substances 0.000 claims abstract description 22
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 21
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 21
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 18
- 241000756943 Codonopsis Species 0.000 claims abstract description 18
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 18
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 18
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 18
- 210000003056 antler Anatomy 0.000 claims abstract description 18
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract description 17
- 235000017491 Bambusa tulda Nutrition 0.000 claims abstract description 17
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims abstract description 17
- 239000011425 bamboo Substances 0.000 claims abstract description 17
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 17
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 15
- 241000894007 species Species 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 79
- 239000000047 product Substances 0.000 claims description 67
- 239000007788 liquid Substances 0.000 claims description 30
- 238000012360 testing method Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 22
- 241001330002 Bambuseae Species 0.000 claims description 16
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 claims description 9
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 claims description 9
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000005057 refrigeration Methods 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 2
- 229920001429 chelating resin Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 53
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract description 3
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 138
- 239000000243 solution Substances 0.000 description 90
- 239000013558 reference substance Substances 0.000 description 58
- 239000008280 blood Substances 0.000 description 43
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- 210000004369 blood Anatomy 0.000 description 39
- 238000004587 chromatography analysis Methods 0.000 description 37
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- 239000012085 test solution Substances 0.000 description 33
- 239000000843 powder Substances 0.000 description 30
- 206010062717 Increased upper airway secretion Diseases 0.000 description 24
- 230000007812 deficiency Effects 0.000 description 24
- 208000026435 phlegm Diseases 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 239000012467 final product Substances 0.000 description 22
- 206010002383 Angina Pectoris Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 15
- 230000036407 pain Effects 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 239000000796 flavoring agent Substances 0.000 description 14
- 235000019634 flavors Nutrition 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 230000010415 tropism Effects 0.000 description 14
- 230000017531 blood circulation Effects 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 235000009508 confectionery Nutrition 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000004575 stone Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 239000000945 filler Substances 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 208000006673 asthma Diseases 0.000 description 8
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000004519 grease Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000002023 wood Substances 0.000 description 6
- DBOVHQOUSDWAPQ-UHFFFAOYSA-N (4aS)-6c-[O2-(3,5,3'-trihydroxy-biphenyl-2-carbonyl)-beta-D-glucopyranosyloxy]-5t-vinyl-(4ar)-4,4a,5,6-tetrahydro-3H-pyrano[3,4-c]pyran-1-one Natural products OC1C(O)C(CO)OC(OC2C(C3C(C(OCC3)=O)=CO2)C=C)C1OC(=O)C1=C(O)C=C(O)C=C1C1=CC=CC(O)=C1 DBOVHQOUSDWAPQ-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- BZXINCMCFVKGKB-UHFFFAOYSA-N Amarogentin Natural products OCC1OC(OC2OC=C3C(CCOC3=O)C2C=C)C(OC(=O)c4cc(O)cc(O)c4c5cccc(O)c5)C(O)C1O BZXINCMCFVKGKB-UHFFFAOYSA-N 0.000 description 5
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N Calycosin Natural products C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 5
- -1 Calycosin glucoside Chemical class 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- DBOVHQOUSDWAPQ-WTONXPSSSA-N amarogentin Chemical compound O([C@H]1[C@H](O[C@H]2[C@@H]([C@H]3C(C(OCC3)=O)=CO2)C=C)O[C@@H]([C@H]([C@@H]1O)O)CO)C(=O)C1=C(O)C=C(O)C=C1C1=CC=CC(O)=C1 DBOVHQOUSDWAPQ-WTONXPSSSA-N 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 206010003549 asthenia Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 208000013220 shortness of breath Diseases 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 4
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 4
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 241000208809 Carthamus Species 0.000 description 3
- 206010009866 Cold sweat Diseases 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 3
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 239000000006 Nitroglycerin Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 240000005809 Prunus persica Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007799 cork Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 3
- 235000011477 liquorice Nutrition 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000002955 secretory cell Anatomy 0.000 description 3
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- FZRCKLPSHGTOAU-UHFFFAOYSA-N 6-amino-1,4-dimethylcyclohexa-2,4-diene-1-carbaldehyde Chemical compound CC1=CC(N)C(C)(C=O)C=C1 FZRCKLPSHGTOAU-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000019890 Amylum Nutrition 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241001573881 Corolla Species 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- YGULWPYYGQCFMP-CEAXSRTFSA-N Metoprolol tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 YGULWPYYGQCFMP-CEAXSRTFSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 230000003760 hair shine Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- MMMUDYVKKPDZHS-MXFZCOKBSA-N (2R,3R,4S,5S,6R)-2-[(4E,6R,7R,12E)-1,7-dihydroxytetradeca-4,12-dien-8,10-diyn-6-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C\C=C\C#CC#C[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)\C=C\CCCO MMMUDYVKKPDZHS-MXFZCOKBSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- MMMUDYVKKPDZHS-UHFFFAOYSA-N (4E,6R,7R,12E)-tetradeca-4,12-dien-8,10-diyne-1,6,7-triol-7-O-beta-D-glucopyranoside Natural products CC=CC#CC#CC(O)C(C=CCCCO)OC1OC(CO)C(O)C(O)C1O MMMUDYVKKPDZHS-UHFFFAOYSA-N 0.000 description 1
- 239000001306 (7E,9E,11E,13E)-pentadeca-7,9,11,13-tetraen-1-ol Substances 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000169680 Aphloia theiformis Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- MMMUDYVKKPDZHS-JGOWZFCDSA-N Lobetyolin Natural products CC=CC#CC#C[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C=CCCCO MMMUDYVKKPDZHS-JGOWZFCDSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229920002522 Wood fibre Polymers 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- MHLMRBVCMNDOCW-UHFFFAOYSA-N acetic acid;butan-1-ol;hydrate Chemical compound O.CC(O)=O.CCCCO MHLMRBVCMNDOCW-UHFFFAOYSA-N 0.000 description 1
- NJUISRMVIKYYCN-UHFFFAOYSA-N acetic acid;chloroform;methanol;hydrate Chemical compound O.OC.CC(O)=O.ClC(Cl)Cl NJUISRMVIKYYCN-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 150000001343 alkyl silanes Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 150000002469 indenes Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- DENOGTWTGDLIBH-SZMQGJMYSA-N lobetyolin Natural products CC=CC#CC#C[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C=CCCO DENOGTWTGDLIBH-SZMQGJMYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical class [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000002025 wood fiber Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于治疗冠心病的中药配方,以下药材种类和重量配比:生黄芪20‑30、党参10‑15、鹿茸2‑5、当归尾8‑14、赤芍10‑14、地龙7‑12、川芎7‑12、红花10‑15、桃仁10‑15、檀香8‑13、竹茹7‑12、天竺黄5‑10、竹沥30‑40、甘草10‑15。本发明配方所生产出来的中药产品对治疗冠心病,对冠心病患者,具有治疗冠心病的显著疗效,无副作用,服用方便,价格低廉。
Description
技术领域
本发明涉及中医中药相关技术领域,特别涉及一种用于治疗冠心病的中药配方。
背景技术
西医认为:冠状动脉性心脏病简称冠心病,是一种常见的心血管疾病,是指因冠状动脉狭窄、供血不足而引起的心肌机能障碍和(或)器质性病变,故又称缺血性心脏病。冠心病是多种冠状动脉病的结果,但冠状动脉粥样硬化占冠状动脉心脏病的绝大多数。因此,习惯上把冠心病视为冠状动脉粥样硬化性心脏病。根据其临床症状,冠心病可分为5型:心绞痛型、心肌梗塞型、无症状性心肌缺血型、心力衰竭和心律失常型、猝死型。《中国心血管病报告2015》数据显示,我国冠心病的患病率和死亡率仍处于上升阶段,严重威胁人们的生命健康。随着老年社会的来临及人们生活水平的提高,心脑血管疾病的发病率逐渐增加,临床上各种心脏病合并心律失常的患者日益增多,而介入治疗的价格昂贵和有创性限制了其在临床上的普及,故西医药物治疗仍是此类疾病治疗的比较常见,但仍有很对不满意的地方。
中医认为:冠心病心绞痛属中医“胸痹”、“真心痛”范畴,病因病机多认为是本虚标实,标实以血瘀、痰浊、气滞、寒凝为主,本虚以气虚、阴虚、阳虚为主,复合证型以气虚痰瘀型和气虚血瘀型为主,针对不同的证型应采取不同的辨证论治。根据此病本虚标实的特点,有医家提倡在治疗该病时,以补为主,以通为用,以益气养阴、活血化瘀、祛痰散结为法。中医治疗冠心病正在越来越发挥着重要作用。因此,发明一种用于治疗冠心病的中药配方来解决上述问题很有必要。
发明内容
本发明属于中医中药技术领域,具体涉及一种用于治疗冠心病患者的中药配方,疗效显著,无副作用。本发明的目的是提供一种中药产品,该产品对治疗冠心病,对冠心病患者,具有治疗冠心病的显著疗效,无副作用,服用方便,价格低廉。
为实现上述目的,本发明提供如下技术方案:一种用于治疗冠心病的中药配方,以下药材种类和重量配比:生黄芪20-30、党参10-15、鹿茸2-5、当归尾8-14、赤芍10-14、地龙7-12、川芎7-12、红花10-15、桃仁10-15、檀香8-13、竹茹7-12、天竺黄5-10、竹沥30-40、甘草10-15。
优选的,以下药材种类和重量配比:生黄芪25、党参12、鹿茸3、当归尾10、赤芍12、地龙8、川穹9、红花10、桃仁10、檀香8、竹茹9、天竺黄8、竹沥35、甘草10。
进一步的,以下药材种类和重量配比:生黄芪20、党参10、鹿茸2、当归尾8、赤芍10、地龙7、川芎7、红花10、桃仁10、檀香8、竹茹7、天竺黄5、竹沥30、甘草10。
进一步的,以下药材种类和重量配比:生黄芪30、党参15、鹿茸5、当归尾14、赤芍14、地龙12、川芎12、红花15、桃仁15、檀香13、竹茹12、天竺黄10、竹沥40、甘草15。
一种用于治疗冠心病的中药配方的制备方法,包括以下步骤:将原料用水浸泡8-12小时,提取罐提取,保持沸腾60分钟,重复二次,将药液抽进浓缩罐,浓缩到相对密度为1.05,冷却,加入4倍量的乙醇,乙醇为95%以上的食用酒精,充分搅拌,静置冷藏12小时,滤过,滤液回收乙醇后,再继续浓缩至稠膏,相对密度为1.35,测定温度为55摄氏度,可采取大孔树脂法除去杂质,加入辅料,辅料为糊精,通过制粒机制粒,流化床干燥温度为60-80℃,再通过整粒,包装,产品检测通过检测黄芪甲苷的含量来定产品是否合格。
本发明选择生黄芪20-30、党参10-15、鹿茸2-5、当归尾8-14、赤芍10-14、地龙7-12、川芎7-12、红花10-15、桃仁10-15、檀香8-13、竹茹7-12、天竺黄5-10、竹沥30-40、甘草10-15作为原料,按配比组合,按照一定的工艺,加工成颗粒剂。
本发明的技术效果和优点:本发明配方所生产出来的中药产品对治疗冠心病,对冠心病患者,具有治疗冠心病的显著疗效,无副作用,服用方便,价格低廉。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
一种用于治疗冠心病的中药配方,以下药材种类和重量配比:生黄芪20-30、党参10-15、鹿茸2-5、当归尾8-14、赤芍10-14、地龙7-12、川芎7-12、红花10-15、桃仁10-15、檀香8-13、竹茹7-12、天竺黄5-10、竹沥30-40、甘草10-15。
本发明中药原料用量,经发明人进行大量摸索总结得出,各原料在以上范围都具有较好的效果,2个月为一个疗程。
实施例一:
本发明选择其中优选为:
一种用于治疗冠心病的中药配方,以下药材种类和重量配比:生黄芪25、党参12、鹿茸3、当归尾10、赤芍12、地龙8、川穹9、红花10、桃仁10、檀香8、竹茹9、天竺黄8、竹沥35、甘草10,2个月为一个疗程。
实施例二:
一种用于治疗冠心病的中药配方,以下药材种类和重量配比:生黄芪20、党参10、鹿茸2、当归尾8、赤芍10、地龙7、川芎7、红花10、桃仁10、檀香8、竹茹7、天竺黄5、竹沥30、甘草10,2个月为一个疗程。
实施例三:
一种用于治疗冠心病的中药配方,以下药材种类和重量配比:生黄芪30、党参15、鹿茸5、当归尾14、赤芍14、地龙12、川芎12、红花15、桃仁15、檀香13、竹茹12、天竺黄10、竹沥40、甘草15。
一种用于治疗冠心病的中药配方的制备方法,包括以下步骤:将原料用水浸泡8-12小时,提取罐提取,保持沸腾60分钟,重复二次,将药液抽进浓缩罐,浓缩到相对密度为1.05,冷却,加入4倍量的乙醇,乙醇为95%以上的食用酒精,充分搅拌,静置冷藏12小时,滤过,滤液回收乙醇后,再继续浓缩至稠膏,相对密度为1.35,测定温度为55摄氏度,可采取大孔树脂法除去杂质,加入辅料,辅料为糊精,通过制粒机制粒,流化床干燥温度为60-80℃,再通过整粒,包装,产品检测通过检测黄芪甲苷的含量来定产品是否合格。
作为原料,按配比组合,按照一定的工艺,加工成颗粒剂。本发明可采取中药制剂的常规方法。
本发明中药配方无副作用,使用方便,价格低廉,根据临床600多案例观察统计,从中选择135例男性作为代表,男性与女性的判断标准相同,发现本发明中药配方总有效率84%。
下面是冠心病患者使用本发明中药配方的临床统计资料:
一般资料:统计治疗治疗组患者75例,男性35例,女30例,平均年龄60±7.34,男:女1.17:1,年龄在50-80之间。对照组患者60例,男性31例,女29例,平均年龄60±7.34,男:女1.07:1,年龄在50-80之间。年龄、性别、中医症候、兼见病没有统计学意义(P≤0.05)。将患者随机分为二组,治疗组与对照组都停用一切中药二周开始,基础药一致,都使用倍他乐克、来适可、拜阿斯匹林,所有按说明书使用。治疗组在使用西药的基础上,使用本发明中药配方,2个月为一个疗程。如患者还有其他病按其他的病治疗,比如高血压按高血压病治疗,高血脂病按高血脂病治疗。按照本发明的方法,每天每个患者服用10克颗粒剂一袋,用温水服下,一般2个月为一个疗程。
2.主要效果观察与判断
观察指标:心电图每二周一次,根据需要,可以加次数,中医症候积分、心绞痛次数、速效救心丸消耗量、中医症候疗效。
临床疗效判断标准:参考《中药新药治疗胸比(冠心病新绞痛)临床指导原则》及《冠心病新绞痛心电图评价标准》为依据。痊愈,与治疗前比较,自觉症状、体征消失,心绞痛症状消失或达到显效标准,
心电图正常,或基本正常;显效,心绞痛自觉症状、体征消失或达到有效标准,心电图改善或基本改善;无效:心绞痛自觉症状无改善、体征无消失或未达到有效标准,心电图相同或基本相同;加重:心绞痛自觉症状加重、体征无消失或加重,心电图较以前加重,如心绞痛的症状与心电图不一致,以疗效低的为准的结果,作为综合疗效。
3.结果分析
按统计分析采用SPSS19.0软件分析,结果以`x±s表示,组间采取t检验,计算资料比较采用χ2检验,以P﹤0.05及P﹤0.01具有统计学意义。
三、治疗方法
1.心绞痛方面的比较
表1,用本发明中药配方对照组与治疗组心绞痛的比较
对照组与治疗组差异显著(P﹤0.05),说明本发明中药配方服用2个月后,有抗心绞痛的疗效。
2.心电图方面的比较
表2,用本发明中药配方对照组与治疗组心电图的比较
对照组与治疗组差异显著(P﹤0.05),说明本发明中药配方服用2个月后,对心电图有较好的改善。
3.速效救心丸消耗量方面的比较
表3,用本发明中药配方对照组与治疗组速效救心丸消耗量的比较
对照组与治疗组差异显著(P﹤0.05),说明本发明中药配方服用2个月后,对速效救心丸消耗量有较大的差别。用本发明中药配方,治疗组本组治疗前后,速效救心丸消耗量的比较,有较大差异,有统计学意义,治疗组与对照组速效救心丸消耗量的比较,有统计学意义。
4.两组患者血脂指标方面的比较
表4、用本发明中药配方对照组与治疗组患者血脂指标方面的比较
以上表说明本发明中药配方服用2个月后,治疗组与对照组比较,TC(mmol/L)、LDL(mmol/L)、HDL(mmol/L)有较大的差别,差异显著(P﹤0.05)。说明用本发明中药配方,对控制血脂有效果,比西药组效果好,有统计学意义。
5.两组患者PLT、ALT、及Cr指标方面的比较
表5、用本发明中药配方对照组与治疗组患者PLT、ALT、及Cr指标方面的比较,ALT代表转氨酶是丙氨酸转氨酶,PLT表示血小板计数。
以上表说明用本发明中药配方,治疗组本组治疗前后ALT及Cr指标比较,有较大差异,有统计学意义,治疗组组内PLT指标比较,无统计学意义,对照组与治疗组比较,ALT、Cr差异显著(P﹤0.05),对照组组内ALT、Cr指标比较,无统计学意义,说明本发明中药配方服用2个月后,对ALT及Cr指标的改善有一定的作用。
6.两组患者LVEF%、CO、SV及△D%(%)、心肌耗氧量指标方面的比较
表6、用本发明中药配方对照组与治疗组患者LVEF%、CO、SV及△D%(%)、心肌耗氧量指标方面的比较,LVEF%为左心室射血分数、CO为心输出量、SV左室博出量,△D%为左室短轴缩短率、心肌耗氧量。
以上表说明用本发明中药配方,治疗组治疗前后,LVEF%、CO、SV及△D%(%)、心肌耗氧量的比较,有较大差异,有统计学意义,治疗组与对照组LVEF%、CO、SV及△D%(%)、心肌耗氧量的比较,有统计学意义,对照组与治疗组差异显著(P﹤0.05),说明本发明中药配方服用2个月后,对冠心病的治疗有较好的效果,其效果好于对照组(西药组)。
八、典型案例
1.某,胸闷不舒,胸前区隐痛不舒,纳食不佳,乏力、气短,有时出冷汗、大便不太通,舌暗红,苔白,有齿痕、脉细汛,来安徽中医药大学第一附属医院诊治,诊断为胸比症,在联合西药的同时(倍他乐克、拜阿斯匹林),同时服用本发明中药配方,通过一诊,二诊。三诊,一个月后,胸闷不舒,胸前区隐痛不舒,纳食不佳,乏力、气短,有时出冷汗、大便不太通,舌暗红,苔白,有齿痕、脉细汛等症状好转,继续服用本发明中药配方20天后,巩固疗效,复查,一切正常。
2.某,男,61岁,安徽合肥人,退休,近年来,时有左胸前区碧门,气短,一出力就心绞痛发作,发作程度不同,精神不好,自感左侧体温低于右侧体温,有时大汗,有时感觉很困,腰酸无力,脉细,舌苔薄,血压140、90,血糖餐前7.6,来安徽中医药大学第一附属医院就诊,诊断为,气虚血瘀痰湿症在联合西药的同时(倍他乐克、拜阿斯匹林),同时服用本发明中药配方,通过一诊,服用本发明中药配方9天后,自觉精神状态好转,随后调理4个月,血糖血压都控制正常,以后开出工作,,只是在劳累过多时,稍有心绞痛的感觉,继续服用本发明中药配方,8个月后,质感很好,以后劳累再无心绞痛的感觉。
3.某,2011年来,男,59岁,安徽合肥人,无业,患者最近几个月一直有心绞痛,有时突然发作,但很快就过,发作时,疼痛难忍。一般在早晨吃完早餐,尤其在寒冷的冬天,激动时,易发作,劳累时易发作,发作严重时,服用舌下含硝酸甘油,很快缓解,最近,发作频繁,质感硝酸甘油的效果不如以前,胸部时间延展,尤其是最近,心绞痛发作时,有时感觉左肩后背都有痛感,气短、有冷汗,有时大汗不得了,夜间难以入睡,脉涩沉,来安徽中医药大学第一附属医院就诊,经诊断,心电图不正常,ST短波下,T波倒置,右束之传导阻滞,中医认为是气虚、痰饮、血瘀症,使用本发明中药配方一个月后,胸痛好转,但仍气短,精神不佳,,症状没有无权消除,继续服用本发明中药配方,一个月后,其他症状都以消除,复查心电图发现,ST波和T波都已正常。随访一年,一切情况良好。
本发明中中药的作用与质量标准
黄芪
【性味】甘、微温。
【归经】归肺、脾经。
【功效】补脾补中、升阳举、益卫固表、利尿、托毒生肌。适用脾气虚、肺气虚、气虚自汗、气血亏虚、燥湿健脾、祛风散寒、湿阻中焦、风湿痹症、风寒夹湿表症。
黄芪甲苷照高效液相色谱法(附录ⅥD)测定。
色谱条件与系统适用性试验以十八烷基硅烷键合硅胶为填充剂;以乙腈水(32:68)为流动相;蒸发光散射检测器检测。理论板数按黄芪甲苷峰计算应不低于4000。对照品溶液的制备取黄芪甲苷对照品适量,精密称定,加甲醇制成每1m1含0.5mg的溶液,即得。供试品溶液的制备取本品中粉约4g,精密称定,置索氏提取器中,加甲醇40m1,冷浸过夜,再加甲醇适量,加热回流4小时,提取液回收溶剂并浓缩至干,残渣加水10ml,微热使溶解,用水饱和的正丁醇振摇提取4次,每次40ml,合并正丁醇液,用氨试液充分洗涤2次,每次40ml,弃去氨液,正丁醇液蒸干,残渣加水5m1使溶解,放冷,通过D101型大孔吸附树脂柱(内径为1.5cm,柱高为12cm),以水50m1洗脱,弃去水液,再用40%乙醇30rnl洗脱,弃去洗脱液,继用70%乙醇80ml洗脱,收集洗脱液,蒸干,残渣加甲醇溶解,转移至5ml量瓶中,加甲醇至刻度,摇匀,即得。测定法分别精密吸取对照品溶液10μl、20μl,供试品溶液20μl注入液相色谱仪,测定,用外标两点法对数方程计算,即得。本品按干燥品计算,含黄芪甲苷(C41H68O14)不得少于0.040%。毛蕊异黄酮葡萄糖苷照高效液相色谱法(附录ⅥD)测定。色谱条件与系统适用性试验以十八烷基硅烷键合硅胶为填充剂;以乙腈为流动性A,以0.2%甲酸溶液为流动相B,按下表中的规定进行梯度洗脱;检测波长为260nm。理论板数按毛蕊异黄酮葡萄糖苷峰计算应不低于3000。时间(分钟)流动相A%流动相B%0~2020→4080→6020~304060,对照品溶液的制备取毛蕊异黄酮葡萄糖苷对照品适量,精密称定,加甲醇制成每1ml含50μg的溶液,即得。供试品溶液的制备取本品粉末(过四号筛)约1g,精密称定.置圆底烧瓶中,精密加入甲醇50ml,称定重量,加热回流4小时,放冷,再称定重量,用甲醇补足减失的重量,摇匀,滤过,精密量取续滤液25ml,回收溶剂至干,残渣加甲醇溶解,转移至jml量瓶中,加甲醇至刻度,摇匀,即得。测定法分别精密吸取对照品溶液与供试品溶液各10μl,注人液相色谱仪,测定,即得。本品按干燥品计算,含毛蕊异黄酮葡萄糖苷(C22H22O10)不得少于0.020%,判为合格。
根据中国药典规定的黄芪药材中皂苷类、黄酮类和多糖类物质的含量,确定了黄芪化学质量标准的评价指标。HPLC-ELS法测定黄芪甲苷的含量,硫酸苯酚法测定黄芪总多糖的含量。黄芪甲苷、总多糖的含量分别为1.186±0.024mg/g、48.800±1.245mg/g为合格。
党参
【性味】甘、平。
【归经】归肺、脾经。
【功效】应用脾肺气虚症、气血两虚症、气津两伤症。
【鉴别】(1)本品横切面:木栓细胞数列至10数列,外侧有石细胞,单个或成群。栓内层窄。韧皮部宽广,外侧常现裂隙,散有淡黄色乳管群,并常与筛管群交互排列。形成层成环。木质部导管单个散在或数个相聚,呈放射状排列。薄壁细胞含菊糖。
(2)取本品粉末1g,加甲醇25ml,超声处理30分钟,滤过,滤液蒸干,残渣加水15m1使溶解,通过D101型大孔吸附树脂柱(内径为1.5cm,柱高为10cm),用水50ml洗脱,弃去水液,再用50%乙醇50ml洗脱,收集洗脱液,蒸干,残渣加甲醇1ml使溶解,作为供试品溶液。另取党参炔苷对照品,加甲醇制成每1ml含1mg的溶液,作为对照品溶液。照薄层色谱法(附录ⅥB)试验,吸取供试品溶液2~4μl、对照品溶液2μl,分别点于同一高效硅胶G薄层板上,以正丁醇冰醋酸水(7:1:0.5)为展开剂,展开,取出,晾干,喷以10%硫酸乙醇溶液,在1。0℃加热至斑点显色清晰,分别置日光和紫外光灯(365nm)下检视。供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的斑点或荧光斑点。【检查】水分不得过16.0%(附录ⅨH第一法)。
总灰分不得过5.0%(附录ⅨK)。【浸出物】照醇溶性浸出物测定法项下的热浸法测定,用45%乙醇作溶剂,不得少于55.0%。
饮片
鹿茸
【性味】甘、咸、温。
【归经】归肾经、肝经。
【功效】补肾阳、益精血、强筋骨、调任冲、托毒,肾阳虚衰、精血不足、肾虚骨弱、腰膝无力。
【鉴别】(1)取本品粉末0.1g,加水4m1,加热15分钟,放冷,滤过,取滤液1ml,加茚三酮试液3滴,摇匀,加热煮沸数分钟,显蓝紫色;另取滤液1ml,加10%氢氧化钠溶液2滴,摇匀,滴加0.5%硫酸铜溶液,显蓝紫色。(2)取本品粉末0.4g,加70%乙醇5ml,超声处理15分钟,滤过,取滤液作为供试品溶液。另取鹿茸对照药材0.4g,同法制成对照药材溶液。再取甘氨酸对照品,加70%乙醇制成每1ml含2mg的溶液,作为对照品溶液。照薄层色谱法(附录ⅥB)试验,吸取供试品溶液和对照药材溶液各8μl、对照品溶液1μl,分别点于同一硅胶G薄层板上,以正丁醇一冰醋酸一水(3:l:1)为展开剂,展开,取出,晾干,喷以2%茚三酮丙酮溶液,在105℃加热至斑点显色清晰。供试品色谱中,在与对照药材色谱相应的位置上,显相同颜色的主斑点;在与对照品色谱相应的位置上,显相同颜色的斑点。
当归尾
【性味】甘、辛、温。
【归经】归肝、心、脾经。
【功效】补血调经、活血止痛、润肠通便。适用血虚诸症,血虚血瘀、月经不调、经闭、痛经,虚寒性腹痛、跌打损伤、痈疽疮疡、风寒痹痛,血虚肠燥便秘。
【鉴别】(1)本品横切面:木栓层为数列细胞。栓内层窄,有少数油室。韧皮部宽广,多裂隙,油室和油管类圆形,直径25~160μm,外侧较大,向内渐小,周围分泌细胞6~9个。形成层成环。木质部射线宽3~5列细胞;导管单个散在或2~3个相聚,呈放射状排列;薄壁细胞含淀粉粒。
粉末淡黄棕色。韧皮薄壁细胞纺锤形,壁略厚,表面有极微细的斜向交错纹理,有时可见菲薄的横隔。梯纹导管和网纹导管多见,直径约至80μm。有时可见油室碎片。
(2)取本品粉末0.5g,加乙醚20ml,超声处理10分钟,滤过,滤液蒸干,残渣加乙醇1ml使溶解,作为供试品溶液。另取当归对照药材0.5g,同法制成对照药材溶液。照薄层色谱法(附录ⅥB)试验,吸取上述两种溶液各10μl,分别点于同一硅胶G薄层板上,以正己烷-乙酸乙酯(4:1)为展开剂,展开,取出,晾干,置紫外光灯(365nm)下检视。供试品色谱中,在与对照药材色谱相应的位置上,显相同颜色的荧光斑点。
(3)取本品粉末3g,加1%碳酸氢钠溶液50ml,超声处理10分钟,离心,取上清液用稀盐酸调节pH值至2~3,用乙醚振摇提取2次,每次20ml,合并乙醚液,挥干,残渣加甲醇1ml使溶解,作为供试品溶液。另取阿魏酸对照品、藁本内酯对照品,加甲醇制成每1m1各含1mg的溶液,作为对照品溶液。照《薄层色谱法检验标准操作程序》(附录ⅥB)试验,吸取上述三种溶液各10μl,分别点于同一硅胶G薄层板上,以环己烷一二氯甲烷一乙酸乙酯一甲酸(4:1:1:0.1)为展开剂,展开,取出,晾干,置紫外光灯(365nm)下检视。供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的荧光斑点。
【含量测定】挥发油照挥发油测定法(附录XD乙法)测定。
本品含挥发油不得少于0.4%(ml/g)。
阿魏酸照《高效液相色谱法检验标准操作程序》测定。
色谱条件与系统适用性试验以十八烷基硅烷键合硅胶为填充剂;以乙腈一0.085%磷酸溶液(17:83)为流动相;检测波长为316nm;柱温35℃。理论板数按阿魏酸峰计算应不低于5000。
对照品溶液的制备取阿魏酸对照品适量,精密称定,置棕色量瓶中,加70%甲醇制成每1ml含12μg的溶液,即得。
供试品溶液的制备取本品粉末(过三号筛)约0.2g,精密称定,置具塞锥形瓶中,精密加人70%甲醇20ml,密塞,称定重量,加热回流30分钟,放冷,再称定重量,用70%甲醇补足减失的重量,摇匀,静置,取上清液滤过,取续滤液,即得。
测定法分别精密吸取对照品溶液与供试品溶液各10μl,注入液相色谱仪,测定,即得。
本品按干燥品计算,含阿魏酸(C10H10O4)不得少于0.050%。
赤芍
【性味】苦、微寒。
【归经】归肝经。
【功效】清热凉血、散瘀止痛。适用温毒发斑、血热吐衄,目赤肿痛、痈肿疮疡,肝郁胁痛、经闭痛经、癥瘕腹痛、跌打损伤。
【鉴别】(1)本品横切面:木栓层为数列棕色细胞。栓内层薄壁细胞切向延长。韧皮部较窄。形成层成环。木质部射线较宽,导管群作放射状排列,导管旁有木纤维。薄壁细胞含草酸钙簇晶,并含淀粉粒。
(2)取本品粉末0.5g,加乙醇10ml,振摇5分钟,滤过,滤液蒸干,残渣加乙醇2ml使溶解,作为供试品溶液。另取芍药苷对照品,加乙醇制成每1ml含2mg的溶液,作为对照品溶液。照《薄层色谱法检验标准操作程序》(附录ⅥB)试验,吸取上述两种溶液各4μl,分别于同一硅胶G薄层板上,以三氯甲烷一乙酸乙酯一甲醇一甲酸(40:5:10:0.2)为展开剂,展开,取出,晾干,喷以5%香草醛硫酸溶液,加热至斑点显色清晰。供试品色谱中,在与对照品色谱相应的位置上,显相同的蓝紫色斑点。
【含量测定】照《高效液相色谱法检验标准操作程序》测定。
色谱条件与系统适用性试验以十八烷基硅烷键合硅胶为填充剂;以甲醇一0.05mol/L磷酸二氢钾溶液(40:65)为流动相;检测波长为230nm。理论板数按芍药苷峰计算应不低于3000。
对照品溶液的制备取经五氧化二磷减压干燥器中干燥36小时的芍药苷对照品适量,精密称定,加甲醇制成每1ml含0.5mg的溶液,即得。供试品溶液的制备取本品粗粉约0.5g,精密称定,置具塞锥形瓶中,精密加入甲醇25ml,称定重量,浸泡4小时,超声处理20分钟,放冷,再称定重量,用甲醇补足减失的重量,摇匀,滤过,取续滤液,即得。
测定法分别精密吸取对照品溶液与供试品溶液各10μ1,注入液相色谱仪,测定,即得。本品含芍药苷(C23H28O11)不得少于1.8%。
地龙
【性味】咸、寒。
【归经】归肝、脾、膀胱经。
【功效】清热定惊、通络、平喘、利尿。适用高热惊痫、癫狂,气虚血滞、半身不遂,痹证,肺热哮喘,小便不利、尿闭不通。
【鉴别】(1)本品粉末淡灰色或灰黄色。斜纹肌纤维无色或淡棕色,肌纤维散在或相互绞结成片状,多稍弯曲,直径4~26μm,边缘常不平整。表皮细胞呈棕黄色,细胞界限不明显,布有暗棕色的色素颗粒。刚毛少见,常碎断散在,淡棕色或黄棕色,直径24~32t~m,先端多钝圆,有的表面可见纵裂纹。
(2)取本品粉末1g,加水10ml,加热至沸,放冷,离心,取上清液作为供试品溶液。另取赖氨酸对照品、亮氨酸对照品、缬氨酸对照品,加水制成每1ml各含1mg、lmg和0.5mg的溶液.作为对照品溶液。照《薄层色谱法检验标准操作程序》(附录ⅥB)试验,吸取上述四种溶液各3μl,分别点于同一硅胶G薄层板上,以正丁醇一冰醋酸一水(4:1:1)为展开剂,展开,取出,晾干,喷以茚三酮试液,在105℃加热至斑点显色清晰。供试品色谱中.存与对照品色谱相应的位置上,显相同颜色的斑点。
(3)取本品粉末lg,加三氯甲烷20ml,超声处理驭)分钟,滤过,滤液蒸干,残渣加三氯甲烷1ml使溶解,作为供试品溶液。另取地龙对照药材1g,同法制成对照药材溶液。照薄层色谱法(附录ⅥB)试验,吸取上述两种溶液各5μl,分别点于同一硅胶G薄层板上,以甲苯一丙酮(9:1)为展开剂,展开,取出,晾干,置紫外光灯(365nm)下检视。供试品色谱中,在与对照药材色谱相应的位置上,显相同颜色的荧光斑点。
川芎
【性味】辛、温。
【归经】归肝、胆、心包经。
【功效】活血行气、祛风止痛。适用血瘀气滞痛证,头痛、风湿痹痛。
【鉴别】(1)本品横切面:木栓层为10余列细胞。皮层狭窄,散有根迹维管束,其形成层明显。韧皮部宽广,形成层环波状或不规则多角形。木质部导管多角形或类圆形,大多单列或排成“V”形,偶有木纤维束。髓部较大。薄壁组织中散有多数油室,类网形、椭圆形或形状不规则,淡黄棕色,靠近彤成层的油室小,向外渐大;薄壁细胞中富含淀粉粒,有的薄壁细胞中含草酸钙晶体,呈类圆形团块或类簇晶状。
粉末淡黄棕色或灰棕色。淀粉粒较多,单粒椭圆形、长圆形、类圆形、卵圆形或肾形,直径5~16μm,长约21μm,脐点点状、长缝状或人字状;偶见复粒,由2~4分粒组成。草酸钙晶体存在于薄壁细胞中,呈类圆形团块或类簇晶状,直径lO~25μm。木栓细胞深黄棕色,表面观呈多角形,微波状弯曲。油室多已破碎,偶可见油室碎片,分泌细胞壁薄,含有较多的油滴。导管主为螺纹导管,亦有网纹导管及梯纹导管,直径14~50μm。
(2)取本品粉末1g,加石油醚(30~60℃)5ml,放置10小时,时时振摇,静置,取上清液1ml,挥干后,残渣加甲醇1ml使溶解,再加2%3,5-二硝基苯甲酸的甲醇溶液2~3滴与甲醇饱和的氢氧化钾溶液2滴,显红紫色。
(3)取本品粉末1g,加乙醚20ml,加热回流l小时,滤过,滤液挥干,残渣加乙酸乙酯2ml使溶解,作为供试品溶液。另取川芎对照药材1g,同法制成对照药材溶液。再取欧当归内酯A对照品,加乙酸乙酯制成每1ml含0.1mg的溶液(置棕色量瓶中),作为对照品溶液。照薄层色谱法(附录ⅥB)试验,吸取上述三种溶液各10μl,分别点于同一硅胶GF254薄层板上,以正己烷-乙酸乙酯(3:1)为展开剂,展开,取出。晾干,置紫外光灯(254nm)下检视。供试品色谱中,在与对照药材色谱和对照品色谱相应的位置上,显相同颜色的斑点。
【含量测定】照高效液相色谱法(附录ⅥD)测定。
色谱条件与系统适用性试验以十八烷基硅烷键合硅胶为填充剂;以甲醇-l%醋酸溶液(30:70)为流动相;检测波长为321nm。理论板数按阿魏酸峰计算应不低于4000。
对照品溶液的制备取阿魏酸对照品适量,精密称定,置棕色量瓶中,加70%甲醇制成每1ml含20μg的溶液,即得。
供试品溶液的制备取本品粉末(过四号筛)约0.5g,精密称定,置具塞锥形瓶中,精密加入70%甲醇50ml,密塞,称定重量,加热回流30分钟,放冷,再称定重量,用70%甲醇补足减失的重量,摇匀,静置,取上清液,滤过,取续滤液,即得。
测定法分别精密吸取对照品溶液与供试品溶液各10μ1.注入液相色谱仪,测定,即得。
本品按干燥品计算,含阿魏酸(C10H1004)不得少于0.10%。
红花
【性味】辛、温。
【归经】归心、肝经。
【功效】活血通经、祛瘀止痛。适用血滞经闭、痛经、产后瘀滞腹痛,癥瘕积聚,胸痹心痛、血瘀腹痛、胁痛,跌打损伤、瘀滞肿痛,瘀滞斑疹色暗。
【鉴别】(1)本品粉末橙黄色。花冠、花丝、柱头碎片多见,有长管状分泌细胞常位于导管旁,直径约至66μm,含黄棕色至红棕色分泌物。花冠裂片顶端表皮细胞外壁突起呈短绒毛状。柱头和花柱上部表皮细胞分化成圆锥形单细胞毛,先端尖或稍钝。花粉粒类圆形、椭圆形或橄榄形,直径约至60μm,具3个萌发孔,外壁有齿状突起。草酸钙方晶存在于薄壁细胞中,直径2~6μm。
(2)取本品粉末0.5g,加80%丙酮溶液5ml,密塞,振摇15分钟,静置,取上清液作为供试品溶液。另取红花对照药材0.5g,同法制成对照药材溶液。照《薄层色谱法检验标准操作程序》(附录ⅥB)试验,吸取上述两种溶液各5μl,分别点于同一硅胶H薄层板上,以乙酸乙酯一甲酸一水一甲醇(7:2:3:0.4)为展开剂,展开,取出,晾干。供试品色谱中.在与对照药材色谱相应的位置上,显相同颜色的斑点。
【含量测定】羟基红花黄色素A照高效液相色谱法(附录ⅥD)测定。
色谱条件与系统适用性试验以十八烷基硅烷键合硅胶为填充剂;以甲醇-乙腈-0.7%磷酸溶液(26:2:72)为流动相;检测波长为403nm。理论板数按羟基红花黄色素A峰计算应不低于3000。
对照品溶液的制备取羟基红花黄色素A对照品适量,精密称定,加25%甲醇制成每1m1含0.13mg的溶液,即得。
供试品溶液的制备取本品粉末(过三号筛)约0.4g,精密称定,置具塞锥形瓶中.精密加入25%甲醇50ml,称定重量,超声处理(功率300W,频率50kHz)40分钟,放冷,再称定重量,用25%甲醇补足减失的重量,摇匀,滤过.取续滤液,即得。
测定法分别精密吸取对照品溶液与供试品溶液各10μl,注入液相色谱仪,测定,即得。本品按干燥品计算,含羟基红花黄色素A(C27H30O15)不得少于1.0%。山柰素照《高效液相色谱法检验标准操作程序》测定。色谱条件与系统适用性试验以十八烷基硅烷键合硅胶为填充剂;以甲醇一0.4%磷酸溶液(52:48)为流动相;检测波长为367nm。理论板数按山柰素峰计算应不低于3000。
对照品溶液的制备取山柰素对照品适量,精密称定,加甲醇制成每1ml含9μg的溶液,即得。供试品溶液的制备取本品粉末(过三号筛)约0.5g,精密称定,置具塞锥形瓶中,精密加入甲醇25ml,称定重量,加热回流30分钟。放冷,再称定重量,用甲醇补足减失的重量,摇匀,滤过,精密量取续滤液15ml,置平底烧瓶中,加盐酸溶液(15→37)5m1,摇匀,置水浴中加热水解30分钟,立即冷却,转移至25ml量瓶中,用甲醇稀释至刻度,摇匀,滤过,取续滤液,即得。测定法分别精密吸取对照品溶液与供试品溶液各10μl,注入液相色谱仪,测定,即得。本品按干燥品计算,含山柰素(C15H10O6)不得少于0.050%。
桃仁
【性味】苦、甘、平。有小毒。
【归经】归心、肝、大肠经。
【功效】活血祛瘀、润肠通便、止咳平喘。适用瘀血阻滞诸症,肺痈、肠痈,肠燥便秘,咳嗽气喘。
【鉴别】(1)本品种皮粉末(或解离)片:桃仁石细胞黄色或黄棕色,侧面观贝壳形、盔帽形、弓形或椭圆形,高54~153μm,底部宽约至180μrn,壁一边较厚,层纹细密;表面观类圆形、圆多角形或类方形,底部壁上纹孔大而较密。山桃仁石细胞淡黄色、橙黄色或橙红色,侧面观贝壳形、矩圆形、椭圆形或长条形,高81~198(279)μm,宽约至128(198)μm;表面观类圆形、类六角形、长多角形或类方形,底部壁厚薄不匀,纹孔较小。
(2)取本品粗粉2g,加石油醚(60~90℃)50ml,加热回流1小时,滤过,弃去石油醚液,药渣再用石油醚25ml洗涤,弃去石油醚,药渣挥干,加甲醇30ml,加热回流1小时,放冷,滤过,取滤液作为供试品溶液。另取苦杏仁苷对照品,加甲醇制成每1ml含2mg的溶液,作为对照品溶液。照薄层色谱法(附录ⅥB)试验,吸取上述两种溶液各5μl,分别点于同一硅胶G薄层板上,以三氯甲烷-乙酸乙酯-甲醇-水(15:40:22:10)5~10℃放置12小时的下层溶液为展开剂,展开,取出,立即喷以磷钼酸硫酸溶液(磷钼酸2g,加水20rnl使溶解,再缓缓加入硫酸30ml,混匀),在105℃加热至斑点显色清晰。供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的斑点。
【含量测定】照高效液相色谱法(附录ⅥD)测定。色谱条件与系统适用性试验以十八烷基硅烷键合硅胶为填充剂;以甲醇-水(20:80)为流动相;检测波长为210nm。理论板数按苦杏仁苷峰计算应不低于3000。对照品溶液的制备取苦杏仁苷对照品适量,精密称定,加70%甲醇制成每lml含苦杏仁苷80μg的溶液,即得。供试品溶液的制备取本品粗粉约0.3g,精密称定,置具塞锥形瓶中,加石油醚(60~90℃)50ml,加热回流1小时,放冷,滤过,弃去石油醚液,药渣及滤纸挥干溶剂,放入原锥形瓶中.精密加入70%甲醇50ml,称定重量,加热回流1小时,放冷,再称定重量,用70%甲醇补足减失的重量,摇匀,滤过。精密量取续滤液5m1,置10ml量瓶中,加50%甲醇至刻度,摇匀,即得。测定法分别精密吸取对照品溶液与供试品溶液各10μl,注入液相色谱仪,测定,即得。本品按干燥品计算,含苦杏仁苷(C20H27NO11)不得少于2.0%。
檀香
【性味】辛、温。
【归经】归脾、胃、、心、肺经。
【功效】行气止痛、散寒调中。适用胸腹寒凝气滞。
【鉴别】(1)本品横切面:导管单个散在,偶有2~3个联合。木射线由1~2列径向延长的细胞组成。木薄壁细胞单个散在或数个联结,有的含草酸钙方晶。导管、射线细胞、木薄壁细胞内均可见油滴。
(2)取本品[含量测定]项下的挥发油,加乙醚制成每1ml含10μ1的溶液,作为供试品溶液。另取檀香醇对照品,加乙醚制成每1ml含5μl的溶液(或用印度檀香的挥发油加乙醚制成每1ml含10μl的溶液)作为对照品溶液。照薄层色谱法(附录ⅥB)试验,吸取上述两种溶液各10μl,分别点于同一硅胶G薄层板上,以石油醚(60~90℃)-乙酸乙酯(17:3)为展开剂,展开,取出,晾干,喷以对二甲氨基苯甲醛溶液(取对二甲氨基苯甲醛0.25g,溶于冰醋酸50g中,加85%磷酸溶液5g与水20ml,混匀),在80~90℃加热至斑点显色清晰。供试品色谱中,在与对照品色谱相应的位置上,显相同的紫蓝色斑点。
竹茹
【性味】甘、微寒。
【归经】归肺、胃经。
【功效】清热化痰、除烦止呕。适用肺热咳嗽、痰热心烦不寐,胃热呕吐、妊娠恶阻。
【性状】本品为卷曲成团的不规则丝条或呈长条形薄片状。宽窄厚薄不等,浅绿色、黄绿色或黄白色。纤维性,体轻松,质柔韧,有弹性。气微,味淡。
天竺黄
【性味】甘、寒。
【归经】归肝、心经。
【功效】清热化痰、清心定惊。适用小儿惊风、中风癫痫、热病神昏,痰热咳喘。
【鉴别】(1)取本品适量,炽灼灰化后,残渣中加盐酸与硝酸的等容混合液,滤过,滤液加钼酸铵试液,振摇,再加硫酸亚铁试液,即显蓝色。
(2)取滤纸1片,加亚铁氰化钾试液1滴,待干后,再加盐酸溶液1滴、水l0滴与0.1%茜红的乙醇溶液1滴,置氨蒸气中熏后,滤纸上可见紫色斑中有红色的环。
竹沥
【性味】甘、寒。
【归经】归心、肺、肝经。
【功效】清热豁痰、定惊利窍。适用痰热咳喘,中风痰迷、惊现癫狂。
【鉴别】以本品为供试品溶液,另取酪氨酸作对照品,加水溶解,制成每1ml中含1mg的对照品溶液。照薄层色谱法试验,吸取上述两种溶液各20μl,分别点于同一硅胶G薄层板上,以正丁醇-醋酸-水(4:1:1)的上层液为展开剂,展开,取出,晾干。喷以0.5%茚三酮乙醇液,于105℃烘约10分钟。供试品色谱中在与对照品色谱相应的位置上,显相同颜色的斑点。
甘草
【性味】甘、平。
【归经】归心、肺、脾、胃经。
【功效】补脾益气、祛痰止咳、缓急止痛、清热解毒、调和诸药。适用心气不足、脉结代、心动悸,脾气虚证,咳喘,脘腹、四肢挛急疼痛,热毒疮疡、咽喉肿痛、药食中毒,调和药性。
【鉴别】(1)本品横切面:木栓层为数列棕色细胞。栓内层较窄。韧皮部射线宽广,多弯曲,常现裂隙;纤维多成束,非木化或微木化,周围薄壁细胞常含草酸钙方晶;筛管群常因压缩而变形。束内形成层明显。木质部射线宽3~5列细胞;导管较多,直径约至160μm;木纤维成束,周围薄壁细胞亦含草酸钙方晶。根中心无髓;根茎中心有髓。
粉末淡棕黄色。纤维成束,直径8~14μm,壁厚,微木化,周围薄壁细胞含草酸钙方晶,形成晶纤维。草酸钙方晶多见。具缘纹孔导管较大,稀有网纹导管。木栓细胞红棕色,多角形,微木化。
(2)取本品粉末1g,加乙醚40ml,加热回流1小时,滤过,弃去醚液,药渣加甲醇30ml,加热回流1小时,滤过,滤液蒸干,残渣加水40ml使溶解,用正丁醇提取3次,每次20ml,合并正丁醇液,用水洗涤3次,弃去水液,正丁醇液蒸于,残渣加甲醇5ml使溶解,作为供试品溶液。另取甘草对照药材1g,同法制成对照药材溶液。再取甘草酸单铵盐对照品,加甲醇制成每lml含2mg的溶液,作为对照品溶液。照《薄层色谱法检验标准操作程序》(附录ⅥB)试验,吸取上述三种溶液各l~2μl,分别点于同一用1%氢氧化钠溶液制备的硅胶G薄层板上,以乙酸乙酯一甲酸一冰醋酸一水(15:l:1:2)为展开剂,展开,取出,晾干,喷以10%硫酸乙醇溶液,在105℃加热至斑点显色清晰,置紫外光灯(365nm)下检视。供试品色谱中,在与对照药材色谱相应的位置上,显相同颜色的荧光斑点;在与对照品色谱相应的位置上,显相同的橙黄色荧光斑点。
【含量测定】照《高效液相色谱法检验标准操作程序》测定。
色谱条件与系统适用性试验以十八烷基硅烷键合硅胶为填充剂,以乙腈为流动相A,以0.05%磷酸溶液为流动相B,按下表中的规定进行梯度洗脱;检测波长为237nm。理论板数按甘草苷峰计算应不低于5000。时间(分钟)流动相A(%)流动相B(%)0~81981,8~3519~5081~50,35~3650~10050~0,36~40100~190~81,对照品溶液的制备取甘草苷对照品、甘草酸铵对照品适量,精密称定,加70%乙醇分别制成每1ml含甘草苷20μg、甘草酸铵0.2mg的溶液,即得(甘草酸重量一甘草酸铵重量/1.0207)。供试品溶液的制备取本品粉末(过三号筛)约O.2g,精密称定,置具塞锥形瓶中,精密加入70%乙醇100ml,密塞,称定重量,超声处理(功率250W,频率40kHz)30分钟,放冷,再称定重量,用70%乙醇补足减失的重量,摇匀,滤过,取续滤液,即得。测定法分别精密吸取对照品溶液与供试品溶液各10μl,注入液相色谱仪,测定,即得。本品按干燥品计算,含甘草苷(C21H22O9)不得少于0.50%,甘草酸(C42H62O16)不得少于2.0%。
现代药理研究表明:生黄芪补脾益气、党参具有抗癌、降压、抗缺氧、抗衰老、抗溃疡、调整胃肠运动、增强机体免疫力、抑制胃酸分泌等功能;鹿茸具有增强机体活力、促进细胞新陈代谢、增强心肌收缩力、增强胃肠蠕动和分泌、调节中枢神经、补肾阳、益经血、壮筋骨等功能;当归尾具有抑制平滑肌、抗血小板聚集、抗炎增强机体免疫功能、脑缺血损伤的保护、抗肿瘤等作用;赤芍具有保肝、抗肿瘤、神经保护、心脏保护、抗血栓、抗氧化的功能;地龙具有降压、抗血栓、抗心律失常、抗癌、增强免疫、抗溃疡、解热镇痛、抗肝纤维化等作用;川芎具有清除氧自由基、钙拮抗、扩血管、抗血小板聚集和血栓形成等作用;红花具有抗血小板聚集、抗氧化、抗衰老、抗肿瘤等作用;桃仁具有心血管保护、神经保护、免疫调节、抗肿瘤及肝肾保护等作用;檀香治疗气滞血瘀之胸痹用于心绞痛;竹茹具有清热化痰、除烦止呕、安胎凉血的作用;天竺黄具有镇痛、抗炎、抗菌和抗肿瘤作用;竹沥具有镇咳、祛痰、平喘等作用。
中医认为:冠心病心绞痛属中医“胸痹”、“真心痛”范畴,病因病机多认为是本虚标实,标实以血瘀、痰浊、气滞、寒凝为主,本虚以气虚、阴虚、阳虚为主,复合证型以气虚痰瘀型和气虚血瘀型为主,针对不同的证型应采取不同的辨证论治。根据此病本虚标实的特点,有医家提倡在治疗该病时,以补为主,以通为用,以益气养阴、活血化瘀、祛痰散结为法。本发明中药配方中黄芪、党参、鹿茸为君药,具有补正气,鼓动血脉、中医认为这是冠心病,因虚而瘀,属冠心病的本,故以补气为主,血瘀为辅,当归尾、赤芍、地龙、川芎、红花、桃仁、檀香为臣药,具有活血通络,活血而不伤血,竹茹、天竺黄、竹沥为佐药,中医认为冠心病是痰而致,冠状动脉变的狭窄,是因为血脉中痰浊较多,故应去痰,甘草调和诸药,为使药。以上所有药放在一起,配伍使气血旺以治本,去痰活血为标,标本兼治,补气而不雍阻滞,活血而不伤正,合而用之,气旺,瘀消、络通,达到治疗的效果。
本发明中药配方根据中医理论,在长期的临床实践中摸索除益气活血化痰法中药复方用于本病的治疗。方中黄芪为君药,起益气养阴的作用,心气旺则血运有力,心脉得畅,心有所养。现代药理学研究表明,黄芪可加强心肌细胞的代谢和补偿能力,使心肌细胞抗缺氧能力提高,还能增强心肌收缩力,扩张冠脉,改善心肌供血,清除自由基,对防止缺血引起的再灌注损伤具有一定的作用。党参具有养阴清肺、益胃生津的功效,与黄芪共为君药,共奏益气养阴之效。方中红花与川芎共为臣药,具有养血活血、化瘀而不伤正的特点,使瘀去而新生,心有所养,心脉得宁,其中川芎含主要成分川芎嗪,新研究表明川芎嗪可扩张冠脉,阻断内皮素受体而有效地拮抗内皮素-1的冠脉收缩效应,防止心肌缺血的发生。实验研究还表明其与红花配伍可阻止细胞凋亡,预防动脉粥样硬化。竹茹清热化痰、宽胸散结,檀香能行气止痛、散寒调中,两药配伍共奏化痰理气开痹功效。甘草能调和药性,为方中佐药,能补益心脾之气,配伍黄芪、川芎、红花等,具有益气活血的功效。本研究显示治疗组在心绞痛疗效、心电图改善及硝酸甘油减量方面均明显优于单纯使用西药的对照组,体现了中医配合西药治疗该病的优势,为中医药治疗冠心病心绞痛从益气活血化痰法论治的可靠疗效提供了进一步的证据。本发明中药配方在临床上的发挥着较大的作用。
通过以上3组实施例均可以制得用于治疗冠心病的中药配方,其中第1组实施例制得的用于治疗冠心病的中药配方效果最好,本发明配方所生产出来的中药产品对治疗冠心病,对冠心病患者,具有治疗冠心病的显著疗效,无副作用,服用方便,价格低廉。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种用于治疗冠心病的中药配方,其特征在于,以下药材种类和重量配比:生黄芪20-30、党参10-15、鹿茸2-5、当归尾8-14、赤芍10-14、地龙7-12、川芎7-12、红花10-15、桃仁10-15、檀香8-13、竹茹7-12、天竺黄5-10、竹沥30-40、甘草10-15。
2.根据权利要求1所述的一种用于治疗冠心病的中药配方,其特征在于,以下药材种类和重量配比:生黄芪25、党参12、鹿茸3、当归尾10、赤芍12、地龙8、川穹9、红花10、桃仁10、檀香8、竹茹9、天竺黄8、竹沥35、甘草10。
3.根据权利要求1所述的一种用于治疗冠心病的中药配方,其特征在于,以下药材种类和重量配比:生黄芪20、党参10、鹿茸2、当归尾8、赤芍10、地龙7、川芎7、红花10、桃仁10、檀香8、竹茹7、天竺黄5、竹沥30、甘草10。
4.根据权利要求1所述的一种用于治疗冠心病的中药配方,其特征在于,以下药材种类和重量配比:生黄芪30、党参15、鹿茸5、当归尾14、赤芍14、地龙12、川芎12、红花15、桃仁15、檀香13、竹茹12、天竺黄10、竹沥40、甘草15。
5.一种如权利要求1-4任意一项所述的用于治疗冠心病的中药配方的制备方法,其特征在于,包括以下步骤:将原料用水浸泡8-12小时,提取罐提取,保持沸腾60分钟,重复二次,将药液抽进浓缩罐,浓缩到相对密度为1.05,冷却,加入4倍量的乙醇,乙醇为95%以上的食用酒精,充分搅拌,静置冷藏12小时,滤过,滤液回收乙醇后,再继续浓缩至稠膏,相对密度为1.35,测定温度为55摄氏度,可采取大孔树脂法除去杂质,加入辅料,辅料为糊精,通过制粒机制粒,流化床干燥温度为60-80℃,再通过整粒,包装,产品检测通过检测黄芪甲苷的含量来定产品是否合格。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810081654.XA CN107998305A (zh) | 2018-01-29 | 2018-01-29 | 一种用于治疗冠心病的中药配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810081654.XA CN107998305A (zh) | 2018-01-29 | 2018-01-29 | 一种用于治疗冠心病的中药配方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107998305A true CN107998305A (zh) | 2018-05-08 |
Family
ID=62066512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810081654.XA Pending CN107998305A (zh) | 2018-01-29 | 2018-01-29 | 一种用于治疗冠心病的中药配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107998305A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109602866A (zh) * | 2019-01-31 | 2019-04-12 | 舒虹 | 一种治疗冠心病的中药组合物、制剂、制备方法及其应用 |
CN112806572A (zh) * | 2021-01-19 | 2021-05-18 | 胡其勇 | 一种治疗冠心病的五谷杂粮粉 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1101556A (zh) * | 1993-10-09 | 1995-04-19 | 周耀群 | 消栓通冲剂及其制备方法 |
-
2018
- 2018-01-29 CN CN201810081654.XA patent/CN107998305A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1101556A (zh) * | 1993-10-09 | 1995-04-19 | 周耀群 | 消栓通冲剂及其制备方法 |
Non-Patent Citations (5)
Title |
---|
任凤兰: "《中国百年百名中医临床家丛书 王国三》", 31 March 2004 * |
李秀英: "补阳还五汤对冠心病心绞痛患者血凝及预后的影响", 《中国医药导报》 * |
林晓忠等: "加味补阳还五汤治疗气虚血瘀型冠心病心绞痛临床观察", 《实用医学杂志》 * |
罗继红等: "邱保国论治冠心病经验", 《四川中医》 * |
陈志明: "益气活血法治疗冠心病50例临床观察", 《湖南中医药导报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109602866A (zh) * | 2019-01-31 | 2019-04-12 | 舒虹 | 一种治疗冠心病的中药组合物、制剂、制备方法及其应用 |
CN112806572A (zh) * | 2021-01-19 | 2021-05-18 | 胡其勇 | 一种治疗冠心病的五谷杂粮粉 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520694B (zh) | 治疗慢性阻塞性肺病稳定期的中药组合物及其制备方法 | |
CN102362881A (zh) | 银杏洋参制剂的生产方法 | |
CN103417904A (zh) | 一种治疗慢性唇炎的中药组合物及其制备方法 | |
CN107998305A (zh) | 一种用于治疗冠心病的中药配方 | |
CN101209334B (zh) | 一种治疗肺癌的药物及其制备方法 | |
CN115252691B (zh) | 一种用于治疗气滞血瘀型冠心病心绞痛的中药组合物 | |
CN106729214A (zh) | 用于治疗痛风的药物及其制备方法 | |
CN103977390B (zh) | 一种生姜洋葱药酒组合物的制备方法及其用途 | |
CN102526676A (zh) | 治疗慢性心力衰竭的中药、制备方法及给药方式 | |
CN103028071B (zh) | 用于治疗腹泻型肠易激综合征的中药组合物及其制备方法 | |
CN105250954B (zh) | 一种治疗肠易激综合征的中药及其制备方法 | |
CN105055967B (zh) | 一种具有辅助降血糖功能的复方保健品及制备方法 | |
CN107007702A (zh) | 一种治疗骨关节病的中药组合物及其制剂 | |
CN103734425B (zh) | 一种山楂叶降糖降脂保健茶及其制备方法 | |
CN106421559A (zh) | 一种治疗高尿酸血症的中药制剂及其制备方法 | |
CN103948754B (zh) | 一种用于治疗肾虚湿热型慢性肾炎的药物及其制备方法 | |
CN105535839A (zh) | 一种治疗结肠癌的中药片剂及其制备方法 | |
CN104352717A (zh) | 一种治疗脾气虚弱型便血的中药制剂及其制备方法 | |
CN108159377A (zh) | 一种用于降尿酸的中药配方 | |
CN104587300A (zh) | 用于治疗急性白血病的中药组合物及其制备方法 | |
CN115414439B (zh) | 一种治疗功能性便秘的中药组合物 | |
CN107929524A (zh) | 一种降脂减肥的款冬花口服液及其制备方法 | |
CN108272941A (zh) | 一种用于治疗慢性乳糜尿的中药配方及其制备方法 | |
CN102935151B (zh) | 一种保肝降酶的药物组合物及其制备方法和用途 | |
CN100563685C (zh) | 一种治疗慢性便秘的中成药-苁蓉通便制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180508 |
|
WD01 | Invention patent application deemed withdrawn after publication |